Bengaluru: MedGenome has announced a majority investment in Mumbai-headquartered Medcare Management Services Pvt. Ltd., a radiology and nuclear medicine company known for its PET-CT and advanced molecular imaging services.
The move is aimed at expanding MedGenome’s integrated diagnostics footprint across western India and advancing its multi-omics–driven care model.
The partnership brings together Medcare’s expertise in nuclear medicine and imaging with MedGenome’s strengths in genomics, advanced science, and data-driven diagnostics, creating a more comprehensive approach to early detection, disease stratification, and treatment planning.
Founded in 2012, Medcare operates four integrated imaging centres across Mumbai (Chembur), Goregaon, Andheri, and Navi Mumbai offering services such as PET-CT, CT, mammography, nuclear medicine scans, and theragnostics.
Over the years, it has built a strong referral network of more than 50 hospitals and physicians, positioning itself as a trusted clinical diagnostics partner in the region.
Medcare’s promoters will continue to lead operations and drive the company’s next phase of growth in collaboration with MedGenome.
Commenting on the development, representatives of Novo Holdings—an investor in MedGenome—said the investment marks a significant step toward building an integrated diagnostics ecosystem in India by combining imaging, pathology, and multi-omics capabilities to enable earlier and more precise diagnoses.
MedGenome’s leadership noted that diagnostics is the critical starting point in disease management and that integrating Medcare strengthens its ability to deliver end-to-end solutions across the patient journey, particularly in oncology and other complex diseases. The company reiterated its focus on improving early and accurate diagnosis while expanding access to affordable precision healthcare.
Nuclear medicine plays a pivotal role in oncology, cardiology, and neurology, supporting both diagnosis and therapy planning. PET-CT imaging, when complemented by genomic testing, can significantly enhance early cancer detection, guide targeted treatment, and improve monitoring outcomes.
The collaboration aligns with MedGenome’s broader strategy to evolve into a fully integrated diagnostics player by combining radiology, pathology, and genomics under a unified platform. The company aims to scale technology-enabled, patient-centric diagnostic services while widening access to advanced precision medicine across India.
Source link
#MedGenome #acquires #majority #stake #Medcare #Management #Services
